Last week, Health and Human Services (HHS) Secretary Xavier Becerra appeared before the U.S. Senate Appropriations Committee to provide testimony on the FY 2024 Funding Request and Budget Justification of the Department of Health and Human Services.
The Drug Price Transparency in Medicaid Act will protect patients, pharmacies, and others from middlemen tactics that drive up prescription drug prices.
NACDS President and CEO Steven C. Anderson released the following statement today following the introduction of pharmacy benefit manager (PBM) reform legislation (HB 1509/SB 1550) in the Florida legislature:
U.S. House Oversight and Accountability Committee expands bipartisan Congressional push to stop pharmaceutical benefit manipulation by middlemen.
Statement outlines specific solutions to patient-manipulation by “PBMs”.
While we all want to move on from COVID-19, doing so should not mean leaving behind millions of Americans who have relied on their trusted, local pharmacies for testing, vaccinations, and care during the pandemic.
Event opens NACDS’ 90th anniversary celebration; brings together pharmacy chains with between four and 250 locations and their supplier partners.
NACDS’ engagement leverages bipartisan momentum for pro-patient, pro-pharmacy PBM reform at state and federal levels.
NACDS: Floridians, all Americans deserve better than the current “pharmaceutical benefit manipulation”
It is a two-year anniversary that patients and pharmacies can appreciate. With a unanimous decision on December 10, 2020, the U.S. Supreme Court upheld an Arkansas law that confronts the damaging tactics of prescription-drug middlemen known as pharmacy benefit managers (PBMs). NACDS had submitted an amicus brief in this case, Rutledge, Attorney General of Arkansas v. Pharmaceutical Care Management Association (PCMA).
